CD22: A Promising Target for Acute Lymphoblastic Leukemia Treatment
Representative in vivo imaging of mice with acute lymphoblastic leukemia (Day 3). Mice treated with m971-derived CD22-CAR T cells had less tumor growth than mice treated with control (mock) T cells (Day 15). Luminescence (brighter color) reflects tumor growth.
There are about 4,000 new cases of acute lymphoblastic leukemia (ALL) in the United States each year. Great improvements have been made in the treatment of ALL, but many patients suffer from side effects of standard therapy and continue to die of this disease. One of the most promising therapeutic strategies includes engineering T cells with a chimeric antigen receptor (CAR) that alters T cell specificity and function to recognize tumor antigens.
Previous clinical studies have shown that CARs targeting CD19 and CD20 molecules in B-cell malignancies such as ALL is a promising new approach, but determining key factors that influence CAR efficacy requires further investigation. Rimas Orentas, Ph.D., and his colleagues in CCR’s Pediatric Oncology Branch set out to design CARs that target CD22, another molecule found on human B cell diseases, and determine what makes a CAR most efficient.
The typical CAR design includes a single-chain variable fragment (scFv) derived from a monoclonal antibody along with a signaling motif from the T cell receptor zeta chain. This design is referred to as first-generation CAR. Adding one (second-generation CAR) or two (third-generation CAR) costimulatory activating motifs from CD28 and 4-1BB to CARs increases their antitumor activity and their longevity in vivo. The researchers used the CD22 scFV to design a series of CAR constructs to determine which design was most effective against leukemia. Each of the constructs had one of three binding domains that target CD22 (BL22, HA22, and m971) fused to transmembrane and signaling sequences derived from the TCR zeta chain, CD28, and 4-1BB. In some of the constructs, the team positioned the binding domain farther from the T cell membrane using an IgG heavy chain constant domain (CH2CH3). Activated T cells were then transduced with the CAR constructs using retroviral gene vectors.
Before testing the CARs, the researchers first investigated CD22 expression on B-cell precursor ALL (BCP-ALL) cell lines and blasts from patients with BCP-ALL. CD22 was found on all of the cell lines and on more than 90 percent of blasts in almost all patients evaluated. Efficacy of the CARs was then tested on the CD22+ BCP-ALL cell lines and blasts. They found that constructs containing the m971 binding domain were better at killing CD22+ leukemia cells than constructs with the BL22 and HA22 binding domains. The team incorporated the antigen binding domains of BL22 and HA22 into their CAR design because earlier studies showed that both have antitumor activity in BCP-ALL. m971 binds a more membrane proximal epitope on CD22 than the other domains, so the researchers concluded that epitope specificity had a major impact on CAR efficacy. The researchers also found that adding the CH2CH3 domain to some of the CARs did not have an impact on potency.
To determine the effects of intracellular T-cell signaling domains on CAR killing ability, the team compared second- and third-generation CAR designs. They found that second-generation CD22-CARs (containing CD28 or 4-1BB) display more potent killing than third-generation CD22-CARs (containing both CD28 and 4-1BB). This was a surprising finding because third-generation CARs are considered to be superior to second-generation CARs. They also found that second-generation CARs produced higher levels of IFN-γ, TNF-α, and IL-2.
The researchers tested the two best second-generation CD22-CARs in mice with leukemia. They found that treatment with the CD22-CARs increased survival significantly. In particular, the CAR expressing the m971 domain was the most effective. Also, whether the second-generation expressed CD28 or 4-1BB did not affect the CARs’ ability to target BCP-ALL.
These findings indicate that CD22 is a promising target for treatment of BCP-ALL and that second generation m971 derived anti-CD22-CARs is a potential therapeutic for patients with this disease. In order to design the most potent CAR, target antigen selection, CAR binding affinity, and incorporation of appropriate signaling and activation domains should be taken into consideration.
Summary Posted: 02/2013
Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, Fitzgerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ. Anti-CD22-chimeric antigen receptors targeting B cell precursor acute lymphoblastic leukemia. Blood 2012 Dec 14. PubMed Link
Reviewed by Miranda L Hanson
Note: All questions should be directed to TellCCR
- T Cells that Recognize HPV Protein Can Target Virus-Infected Cells
- Pancreatic Cancer Sensitive to Selective p38 Pathway Inhibition
- Mutations Allow JC Polyomaviruses to Elude Antibody Recognition
- Mitochondrial DNA Unwinding Enzyme Required for Liver Regeneration
- Regulatory RNA Key Player in p53-Mediated Apoptosis in Embryonic Stem Cells
- New Method for Producing Significant Amounts of RNA Labeled at Specific Sites
- Mutant HABP2 Causes Non-Medullary Thyroid Cancer
- Paradigm Shift in Thyroid Hormone Mechanism of Action
- Changes in Bacteria Induce Inflammatory Skin Diseases
- Synthetic Spores Give Insight into the Real Thing and Reveal Functional Applications
- Splicing Modulation as a Potential Treatment for Vemurafenib-Resistant Melanoma
- Hepatic Stellate Cells Alter Liver Immune Environment to Promote Cancer
- Adoptive T-cell Therapy Promising for Metastatic Cervical Cancer
- Stop Stalling: Mus81 Required for Efficient Replication